Thursday November 26 2009 | Biotechnology feed | All feeds
|
|
PrognostiX, Inc.
Download detailed PDF Members: PrognostiX, Inc. is a medical diagnostics company. Our technology is based on the unique role of inflammatory processes in major disease areas including cardiovascular, respiratory, neurodegenerative disease and obesity. We are developing new and innovative diagnostic products that enhance and improve medical care.PrognostiX is marketing the CardioMPO™ ELISA based test kit for in vitro diagnostic use. The CardioMPO™ Test measures myeloperoxidase (MPO) levels in human plasma and is intended for use as an aid in evaluating patients presenting with chest pain that are at risk for major adverse cardiac events (MACE), including myocardial infarction, need for revascularization, or death. CardioMPO™ is expected to launch September 1, 2005. The CardioMPO™ Test is also available through our CLIA-certified clinical reference lab.PrognostiX has several additional key products in the pipeline. Like CardioMPO™, these are based on inflammatory biomarkers
This page has been viewed 576 times since April 2007, the link to the organisation's website has been followed 85 times Recent Search Terms used to find this page: jobs at prognostix reference | cardiompo | cardiompo | prognostix logo | PrognostiX stock | prognostix | PrognostiX stock | myeloperoxidase ELISA (PrognostiX, Inc) | Prognostix inc | MPO-ELISA Prognostix | . Search for more companies in Cleveland Search for more companies in Ohio This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for PrognostiX, Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||
|